A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies

Cancer

Volumn 118, Issue 21, 2012, Pages 5403-5413

  Pishvaian, Michael J ^a   Marshall, John L ^a   Wagner, Andrew J ^b   Hwang, Jimmy J ^a   Malik, Shakun ^a   Cotarla, Ion ^a   Deeken, John F ^a   He, A Ruth ^a   Daniel, Hirut ^a   Halim, Abdel Baset ^c   Zahir, Hamim ^c   Copigneaux, Catherine ^c   Liu, Kejian ^c   Beckman, Robert A ^c   Demetri, George D ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

biomarker; CS 7017; efatutazone; phase 1; PPAR ; retinoid

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; DIURETIC AGENT; EFATUTAZONE; FUROSEMIDE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRAVASTATIN; RETINOID X RECEPTOR; SPIRONOLACTONE;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; COUGHING; DISEASE CONTROL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; ENZYME ACTIVITY; FACE EDEMA; FATIGUE; FEMALE; FLUID RETENTION; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; INCREASED APPETITE; INSOMNIA; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; MYXOSARCOMA; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84867888940     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27526     Document Type: Article

References (32)

1. Kersten S, Desvergne B, Wahli W,. Roles of PPARs in health and disease. Nature. 2000; 405: 421-424.
2. Rosen ED, Spiegelman BM,. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001; 276: 37731-37734.
3. Berger J, Moller DE,. The mechanisms of action of PPARs. Annu Rev Med. 2002; 53: 409-435.
4. Kopelovich L, Fay JR, Glazer RI, Crowell JA,. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther. 2002; 1: 357-363.
5. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A. 1997; 94: 237-241.
6. Tontonoz P, Hu E, Spiegelman BM,. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994; 79: 1147-1156.
7. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999; 96: 3951-3956.
8. Brockman JA, Gupta RA, Dubois RN,. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998; 115: 1049-1055.
9. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998; 4: 1046-1052.
10. Gupta RA, Tan J, Krause WF, et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A. 2000; 97: 13275-13280.
11. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer. 2000; 83: 1394-1400.
12. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998; 58: 3344-3352.
13. Clay CE, Atsumi GI, High KP, Chilton FH,. Early de novo gene expression is required for 15-deoxy-Delta 12,14-prostaglandin J2-induced apoptosis in breast cancer cells. J Biol Chem. 2001; 276: 47131-47135.
14. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002; 105: 2296-2302.
15. Goke R, Goke A, Goke B, El-Deiry WS, Chen Y,. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion. 2001; 64: 75-80.
16. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD,. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999; 1: 330-339.
17. Kitamura S, Miyazaki Y, Hiraoka S, et al. PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int J Cancer. 2001; 94: 335-342.
18. Rumi MA, Sato H, Ishihara S, Ortega C, Kadowaki Y, Kinoshita Y,. Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands. J Lab Clin Med. 2002; 140: 17-26.
19. Shao J, Sheng H, DuBois RN,. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 2002; 62: 3282-3288.
20. Bren-Mattison Y, Meyer AM, Van Putten V, et al. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol. 2008; 73: 709-717.
21. Fogarty S, Hardie DG,. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010; 1804: 581-591.
22. Nemenoff RA, Weiser-Evans M, Winn RA,. Activation and molecular targets of peroxisome proliferator-activated receptor-gamma ligands in lung cancer. PPAR Res. 2008; 2008: 156875.
23. Burgermeister E, Seger R,. PPARgamma and MEK interactions in cancer. PPAR Res. 2008; 2008: 309469.
24. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A. 2000; 97: 10990-10995.
25. Degli Esposti R, Scopece L, Cavallo G, et al. Medical management of unresectable, recurrent retroperitoneal liposarcoma (LS) with peroxisome proliferator-activated receptor (PPAR-γ) ligands [abstract]. Proc Am Soc Clin Oncol. 2003; 22. Abstract 3338.
26. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007; 25: 1476-1481.
27. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006; 25: 2304-2317.
28. Shimazaki N, Togashi N, Hanai M, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer. 2008; 44: 1734-1743.
29. Sharma C, Pradeep A, Wong L, Rana A, Rana B,. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem. 2004; 279: 35583-35594.
30. Richards DA, Oettle H, Vervenne WL, et al. Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas [abstract]. J Clin Oncol. 2005; 23 (16s). Abstract 4092.
31. Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus. Clin Pharmacol Ther. 2007; 82: 275-281.
32. Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M, Abollo-Jimenez F, Pintado B, Sanchez-Garcia I,. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. PLoS One. 2008; 3: e2569.